Blurred Boundaries: The Therapeutics and Politics of Medical Marijuana.

submitted by: WentzMR

Dr. J. Michael Bostwick, Professor of psychiatry at Mayo Clinic in Rochester, MN, discusses his article appearing in the February 2012 issue of Mayo Clinic Proceedings on the potential benefits and current legal limitations for including marijuana in medical research. Available at: http://www.mayoclinicproceedings.org/article/S0025-6196(11)00021-8/fulltext

Cannabinoids

submitted by: alex01
Daniele Piomelli, PhD. - Another approach was discussed by D. Piomelli (University of California, Irvine). URB 597, an inhibitor of fatty acid amide hydrolase (FAAH), is expected to increase anandamide signaling and is being currently clinically tested in the therapy of pain. An increase in anandamide signaling may also be useful in the therapy of depression. This is a novel approach to the development of antidepressants. The signaling can be enhanced by blocking anadamide metabolism or by...